Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
21m agoNayax to Report 2026 Q1 Earnings on May 12, 2026
48m agoCC Capital and OneIM Complete Acquisition of Insignia Financial Limited, Australia's Leading Diversified Wealth Management Group
1h agoCanadian Gold Resources Strengthens Board with Capital Markets Veteran Kenneth Chernin
1h agoWaraba Gold Signs Binding Agreement to Establish Joint Venture Relating to Tengrela South Exploration Permit Application in Cote d'Ivoire
1h agoSierra Madre Announces Shareholder Approval of Acquisition of Del Toro Silver Mine
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd

About

Regencell Bioscience Holdings Ltd (NASDAQ:RGC) — investor relations, events, news, and company updates on 6ix.

Latest News

Sep 12 2022
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
May 18 2022
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
May 16 2022
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
Mar 1 2022
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
Feb 16 2022
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

Financials

Revenue
$0
Market Cap
$15.23 B
EPS
-0.01

Community Chat

Ask AI

6ix6ix